All News
View More
Myqorzo is now available for rare heart condition at a $108,400 annual price

Myqorzo was approved in December to treat adults with obstructive hypertrophic cardiomyopathy. It is available through a REMS program and has a boxed warning about the risk of heart failure.

When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
Part D adherence measures save billions, says Ben Shirley of PQA | Part 1
Medicaid tech companies pledge $600 million to help states update systems

Ten Medicaid tech companies pledge over $600 million in support to help states meet new community engagement requirements and modernize eligibility systems.

Shingles vaccine protects against shingles, slows biological aging

A recent study found that older adults who received the shingles vaccine were biologically younger than those who didn’t, which suggests the vaccine may slow aspects of biological aging as well as prevent shingles.

FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare

Explore the impact of ACA tax credits on enrollment, premiums and healthcare access as Congress debates subsidy extensions for 2026 and beyond.

FDA approves combination therapy for blurry vision

Yuvezzi is the first combination product that treats adults with presbyopia. It will be available in the second quarter of 2026.

Higher use, not higher prices, drove a 50% spike in urgent care spending

Urgent care spending surges over 50% from 2018 to 2022, driven by increased visits, highlighting its vital role in healthcare access.

Medicaid expansion associated with lower overall breast cancer mortality

Although Medicaid expansion has been linked to lower mortality, significant racial disparities persist.

Official Media Partners